Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis

We aimed to detail the effects of hydroxyethyl starch (HES) vs. Ringer's on kidney function including the interaction with mortality in post‐hoc analyses as resuscitation with HES 130/0.42 increased mortality in the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial.

[1]  Maria Sudell,et al.  Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis , 2016, BMC Medical Research Methodology.

[2]  S. Evans.  Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock , 2015, Journal of the Intensive Care Society.

[3]  Omid Azizi Farzan Modarresi,et al.  Published by John Wiley & Sons Ltd , 2015 .

[4]  N. Roewer,et al.  Molecular Size and Origin Do Not Influence the Harmful Side Effects of Hydroxyethyl Starch on Human Proximal Tubule Cells (HK-2) In Vitro , 2014, Anesthesia and analgesia.

[5]  R. Bellomo,et al.  Mortality in patients with hypovolemic shock treated with colloids or crystalloids. , 2014, JAMA.

[6]  R. Bellomo,et al.  Open letter to the Executive Director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation. , 2014, British journal of anaesthesia.

[7]  M. Wilkes,et al.  Postoperative renal replacement therapy after hydroxyethyl starch infusion: a meta-analysis of randomised trials , 2014 .

[8]  R. Bellomo,et al.  Hydroxyethyl starch: putting patient safety first , 2014, Intensive Care Medicine.

[9]  M. Joannidis,et al.  Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review , 2013, Intensive Care Medicine.

[10]  C. Seymour,et al.  Making a pragmatic choice for fluid resuscitation in critically ill patients. , 2013, JAMA.

[11]  Sylvie Chevret,et al.  Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. , 2013, JAMA.

[12]  J. Wetterslev,et al.  Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial , 2013, Intensive Care Medicine.

[13]  J. Wetterslev,et al.  Effects of hydroxyethyl starch in subgroups of patients with severe sepsis: exploratory post-hoc analyses of a randomised trial , 2013, Intensive Care Medicine.

[14]  V. Pettilä,et al.  Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units , 2013, Acta anaesthesiologica Scandinavica.

[15]  A. Girbes,et al.  Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement , 2013, Critical Care.

[16]  C. Ruth,et al.  Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. , 2013, The Cochrane database of systematic reviews.

[17]  A. Schramko.  Removal of colloids: evidence‐ or emotional‐based medicine? , 2013, Acta anaesthesiologica Scandinavica.

[18]  E. Ruokonen,et al.  Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study , 2013, Intensive Care Medicine.

[19]  A. Mebazaa,et al.  Year in review in Intensive Care Medicine 2012: I. Neurology and neurointensive care, epidemiology and nephrology, biomarkers and inflammation, nutrition, experimentals , 2012, Intensive Care Medicine.

[20]  R. Bellomo,et al.  Hydroxyethyl starch or saline for fluid resuscitation in intensive care. , 2012, The New England journal of medicine.

[21]  B. Kahan,et al.  Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis , 2012, BMJ : British Medical Journal.

[22]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[23]  Stijn Vansteelandt,et al.  A simple unified approach for estimating natural direct and indirect effects. , 2012, American journal of epidemiology.

[24]  J. Tenhunen,et al.  Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. , 2012, The New England journal of medicine.

[25]  Dimitris Rizopoulos.  39 51 68 82 90 93 148 173 200 242 269 290 Time (years) , 2012 .

[26]  Dimitris Rizopoulos.  Event Time Event Time , 2012 .

[27]  B. Guidet,et al.  Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study , 2012, Critical Care.

[28]  B. Kahan,et al.  Improper analysis of trials randomised using stratified blocks or minimisation , 2012, Statistics in medicine.

[29]  A. Mebazaa,et al.  Year in review in Intensive Care Medicine 2011: I. Nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals , 2012, Intensive Care Medicine.

[30]  R. Bellomo,et al.  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.

[31]  T. Wilt,et al.  A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[32]  George Davey Smith,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[33]  D. Park.  Year in review. , 1997, Hawaii dental journal.

[34]  H E de Wardener,et al.  Effect of urinary extracts from salt-loaded man on urinary sodium excretion by the rat. , 1972, Kidney international.